Alendronate, Etidronate, Risedronate, Raloxifene, Teriparatide and Strontium Ranelate.
Exploring the effect of the efficacy of strontium ranelate in preventing hip fracture in relation to cost-effectiveness (October 2010) (Report academic in confidence)
Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women / alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women – a review of comments submitted by consultees on the economic model (PDF, 692KB) (August 2009)
Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the cost-effectiveness of risedronate and strontium ranelate in those people who would be treated with generic alendronate (PDF, 204KB) (February 2008)
A world top-100 university
We're a world top-100 university renowned for the excellence, impact and distinctiveness of our research-led learning and teaching.